{"disease":{"id":"genotype","name":"genotype"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (genotype 1)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odv-25-mg","indication_name":"Chronic Hepatitis C (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODV 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":0,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT04974138","title":"China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":32000,"lead_sponsor_name":"Shenzhen Ausa Pharmed Co.,Ltd","has_results":false},{"nct_id":"NCT04974151","title":"China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"Shenzhen Ausa Pharmed Co.,Ltd","has_results":false},{"nct_id":"NCT05916287","title":"FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth Visit of the STANISLAS Cohort","phase":"NA","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT00001284","title":"Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers","phase":"","overall_status":"COMPLETED","enrollment_count":2802,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02167945","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03318042","title":"Genotype, Metabotype and Diet in a Cohort of Children and Adolescents From the Southeast of Spain.","phase":"NA","overall_status":"COMPLETED","enrollment_count":423,"lead_sponsor_name":"National Research Council, Spain","has_results":false},{"nct_id":"NCT04155515","title":"A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":370,"lead_sponsor_name":"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT01145196","title":"Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene","phase":"","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT02581163","title":"Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium","phase":"","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT01425203","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":238,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07085533","title":"Natural History Study of Inherited Retinal Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Zhongmou Therapeutics","has_results":false},{"nct_id":"NCT02247401","title":"Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02669940","title":"Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation","phase":"","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02960893","title":"Trial in Adult Participants With Spinocerebellar Ataxia (SCA)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":141,"lead_sponsor_name":"Biohaven Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03151096","title":"Pilot Evaluation of the Effect of Riboflavin Supplementation on Blood Pressure and Possible Effect Modification by the MTHFR C677T Genotype","phase":"NA","overall_status":"TERMINATED","enrollment_count":133,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT03593447","title":"To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03485846","title":"Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"R-Pharm","has_results":false},{"nct_id":"NCT04246723","title":"Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"R-Pharm","has_results":false},{"nct_id":"NCT01441141","title":"Genetics and Pain Severity in Sickle Cell Disease","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03679598","title":"Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT06319391","title":"Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Ziqiang Li","has_results":false},{"nct_id":"NCT06199232","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":47,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT03080415","title":"Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Yassin Abdelghaffar Charity Center for Liver Disease and Research","has_results":false},{"nct_id":"NCT01194037","title":"A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"HanAll BioPharma Co., Ltd.","has_results":false},{"nct_id":"NCT03743727","title":"Treatment of Egyptian Hepatitis C Genotype 4 Infected Children and Adolescents With Combined Ledipasvir/Sofosbuvir","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Yassin Abdelghaffar Charity Center for Liver Disease and Research","has_results":false},{"nct_id":"NCT07138963","title":"Phenotype - Genotype Correlation in a Sample of Egyptian Patients With Congenital Myopathies and Congenital Muscular Dystrophies","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT05623059","title":"Evaluate Pharmacokinetics and Safety of Slow Release DHEA","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT02759861","title":"Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT02863588","title":"Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis","phase":"NA","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT05449080","title":"Disorders of Sex Development (DSD) 46.XY in Three Siblings","phase":"","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Universitas Padjadjaran","has_results":false},{"nct_id":"NCT00882193","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"University of Nebraska","has_results":false}],"total":32},"guidelines":[],"source":"Drug Landscape verified database"}